Report post

Should you buy AbbVie (abbv) stock?

Morgan Stanley analyst Terence Flynn has maintained their bullish stance on ABBV stock, giving a Buy rating on May 21. Terence Flynn has given his Buy rating due to a combination of factors surrounding AbbVie’s strong financial outlook and promising developments in their product pipeline.

What happened to AbbVie (abbv)?

The latest trading session saw AbbVie (ABBV) ending at $160.19, denoting a -0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.11% gain on the day. On the other hand, the Dow registered a loss of 0.3%, and the technology-centric Nasdaq increased by 0.56%.

How did AbbVie's revenue grow over 3 months?

Revenue Growth: AbbVie's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 0.7%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers.

The World's Leading Crypto Trading Platform

Get my welcome gifts